Novanta (NASDAQ:NOVT – Get Free Report) updated its first quarter earnings guidance on Tuesday. The company provided EPS guidance of $0.63-$0.71 for the period, compared to the consensus EPS estimate of $0.78. The company issued revenue guidance of $232-$236 million, compared to the consensus revenue estimate of $245.18 million. Novanta also updated its FY 2025 guidance to 3.350-3.550 EPS.
Analysts Set New Price Targets
Separately, Robert W. Baird reduced their price objective on shares of Novanta from $175.00 to $169.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th.
Check Out Our Latest Stock Analysis on Novanta
Novanta Price Performance
Novanta (NASDAQ:NOVT – Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The technology company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.05. The firm had revenue of $238.10 million during the quarter, compared to analysts’ expectations of $240.29 million. Novanta had a return on equity of 15.20% and a net margin of 6.52%. The company’s revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 earnings per share. As a group, research analysts expect that Novanta will post 3.03 EPS for the current fiscal year.
Novanta Company Profile
Novanta, Inc engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products.
Further Reading
- Five stocks we like better than Novanta
- What is the MACD Indicator and How to Use it in Your Trading
- February’s Top 3 Stock Upgrades: What Investors Need to Know
- Short Selling: How to Short a Stock
- 2 Safe-Haven Stocks Shielded From Import Tariffs
- Health Care Stocks Explained: Why You Might Want to Invest
- Nebius Group: A Strategic Entry Point for Investors?
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.